Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 27
- Registration Number
- NCT06418724
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
- Conditions
- Melanoma Brain Metastases
- Interventions
- Radiation: Hypofractionated stereotactic radiotherapy
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 46
- Registration Number
- NCT06163820
- Locations
- 🇦🇺
Alfred Health, Melbourne, Victoria, Australia
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
- Conditions
- Solid Organ Transplant RecipientsSkin Cancer
- Interventions
- Other: Placebo
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 146
- Registration Number
- NCT05860881
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺The Prince Charles Hospital, Chermside, Queensland, Australia
Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients
- Conditions
- MelanomaSkin CancerAnxiety and Fear
- Interventions
- Device: 2D or 3D Melanoma Surveillance Photography
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 670
- Registration Number
- NCT04385732
- Locations
- 🇦🇺
Skin Health Institute, Carlton, Victoria, Australia
🇦🇺Wonthaggi Hospital, Bass Coast Health, Wonthaggi, Victoria, Australia
🇦🇺Newcastle Skin Check, Newcastle, New South Wales, Australia
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
- Conditions
- Neuroendocrine TumorsMerkel Cell Carcinoma, Stage IMerkel Cell Carcinoma, Stage IIMerkel Cell CarcinomaCarcinoma Neuroendocrine SkinMerkel Cell Carcinoma, Stage III
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 122
- Registration Number
- NCT04291885
- Locations
- 🇦🇺
Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia
🇦🇺Chris O'Brien Lifehouse, Sydney, New South Wales, Australia
🇦🇺Melanoma Institute Australia, Sydney, New South Wales, Australia
Targeted Therapy and Avelumab in Merkel Cell Carcinoma
- Conditions
- Metastatic Merkel Cell Carcinoma
- Interventions
- Radiation: External Beam Radiation Therapy (EBRT)Radiation: Lutetium-177 (177Lu)-DOTATATE
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 19
- Registration Number
- NCT04261855
- Locations
- 🇦🇺
Mid North Coast Cancer Institute - Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia
🇦🇺Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
🇦🇺Gosford Hospital, Gosford, New South Wales, Australia
Improving Skin Cancer Management With Artificial Intelligence (04.17 SMARTI)
- Conditions
- Skin CancerMelanoma (Skin)
- Interventions
- Device: Molemap Skin Cancer Triage Artificial Intelligence Device
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 200
- Registration Number
- NCT04040114
- Locations
- 🇦🇺
Skin Health Institute, Melbourne, Victoria, Australia
🇦🇺The Alfred- Victorian Melanoma Service, Melbourne, Victoria, Australia
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- Conditions
- Cutaneous Melanoma, Stage II
- Interventions
- Procedure: Wide Local Excision = 2cm MarginProcedure: Wide Local Excision = 1cm Margin
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 2998
- Registration Number
- NCT03860883
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Orange, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
- Conditions
- Melanoma Stage IvMelanoma Stage IiiMelanoma
- Interventions
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 72
- Registration Number
- NCT03161756
- Locations
- 🇦🇺
Royal Hobart Hospital, Hobart, Tasmania, Australia
🇦🇺Box Hill Hospital, Box Hill, Victoria, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Radiotherapy or Imiquimod in Complex Lentigo Maligna
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Melanoma and Skin Cancer Trials Limited
- Target Recruit Count
- 126
- Registration Number
- NCT02394132
- Locations
- 🇳🇿
North Shore Hospital, Takapuna, Auckland, New Zealand
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Skin and Cancer Foundation, Sydney, New South Wales, Australia